Sino Biopharmaceutical 

$13.01
44
-$1.36-9.46% Monday 20:00

Statistics

Day High
12.01
Day Low
12.01
52W High
20.16
52W Low
11.27
Volume
1
Avg. Volume
43
Mkt Cap
244.08B
P/E Ratio
33.37
Dividend Yield
2.35%
Dividend
0.31

Upcoming

Dividends

2.35%Dividend Yield
Aug 26
$0.13
Oct 25
$0.13
Jul 25
$0.10
Oct 24
$0.08
Jul 24
$0.08
10Y Growth
N/A
5Y Growth
4.43%
3Y Growth
-5.8%
1Y Growth
42.97%

Earnings

19AugExpected
Q3 2023
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Q2 2026
0
0.07
0.15
0.22
Expected EPS
0.13847930712
Actual EPS
0.2196051012078

Financials

7.21%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
4.49BRevenue
323.63MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SBHMY. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Zai Lab Limited
ZLAB
Mkt Cap2.93B
Zai Lab Limited is involved in the discovery, development, and commercialization of innovative healthcare products, directly competing with Sino Biopharmaceutical's diverse portfolio in the Chinese market.
HUTCHMED (China) Limited
HCM
Mkt Cap2.15B
Hutchison China MediTech Limited, operating in the biopharmaceutical sector, focuses on oncology and immunology, which are also primary areas of focus for Sino Biopharmaceutical, making them direct competitors.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG, through its pharmaceuticals division, competes globally, including in China, in areas such as oncology, where Sino Biopharmaceutical also has significant investments.
Sanofi
SNY
Mkt Cap107.39B
Sanofi operates globally in the pharmaceutical sector, including China, and its activities in areas like immunology and oncology make it a competitor to Sino Biopharmaceutical.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. is a global pharmaceutical corporation with a broad product portfolio that includes treatments in areas where Sino Biopharmaceutical is active, such as oncology, making them competitors.
Novartis
NVS
Mkt Cap292.35B
Novartis AG, a global healthcare company, competes in various therapeutic areas including those that Sino Biopharmaceutical targets, such as oncology and immunology.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. is a global healthcare company that develops pharmaceuticals in key areas like oncology, directly competing with Sino Biopharmaceutical's product range.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca PLC, a global biopharmaceutical company, competes in the development of medicines in oncology, cardiovascular, renal, metabolism, and respiratory diseases, areas that overlap with Sino Biopharmaceutical's interests.

About

Sino Biopharmaceutical Limited operates as a prominent research and development-centric pharmaceutical conglomerate in the People's Republic of China, functioning as an investment holding company. Its operations are organized into three primary divisions: Modernized Chinese and Chemical Medicines, Investment activities, and other varied business ventures. The firm maintains an extensive product range covering numerous therapeutic categories. Among its offerings are oncology treatments, such as Qingkeshu tablets and Leweixin injections; cardiovascular and cerebrovascular medications, including Kaina and Anrixin tablets; hepatitis remedies like Tianqingganmei injections; and orthopedic solutions exemplified by Gaisanchun capsules. The company also produces drugs for respiratory ailments and parenteral nutritional support, for instance, Xinhaineng injections, along with a broad spectrum of other pharmaceutical preparations, such as Tuotuo tablets. Additionally, Sino Biopharmaceutical provides a selection of advanced pharmaceutical agents, including Aprepitant, Lenvatinib Mesilate, Vortioxetine Hydrobromide, and Edaravone injection. Its portfolio also features combination therapies like Amlodipine Besylate and Atorvastatin Calcium, alongside Sofosbuvir, Sitagliptin Phosphate, Colistimethate Sodium for injection, and Tofacitinib Citrate. Beyond its core pharmaceutical manufacturing, the company's diverse business interests encompass property holdings, the retail and distribution of pharmaceutical products, and providing optometry services coupled with the sale of ophthalmic goods. It manages hospitals, delivers medical management and health information consultancy, and offers biotechnology transfer and consultation services. The enterprise is also involved in the production and sale of health foods, provides orthopedic outpatient care and surgical procedures, engages in medical and health technology development, trades optical glasses, and conducts research, development, and commercialization of medical devices and active pharmaceutical ingredients. Established in 2000, the company's corporate headquarters are situated in Wan Chai, Hong Kong.
Show more...
CEO
S. Y. Tse
Employees
21435
Country
Cayman Islands
ISIN
US82937X1037

Listings

0 Comments

Share your thoughts

FAQ

What is Sino Biopharmaceutical stock price today?
The current price of SBHMY is $13.01 USD — it has decreased by -9.46% in the past 24 hours. Watch Sino Biopharmaceutical stock price performance more closely on the chart.
What is Sino Biopharmaceutical stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Sino Biopharmaceutical stocks are traded under the ticker SBHMY.
Is Sino Biopharmaceutical stock price growing?
SBHMY stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Sino Biopharmaceutical has showed a -35.47% decrease.
What is Sino Biopharmaceutical market cap?
Today Sino Biopharmaceutical has the market capitalization of 244.08B
When is the next Sino Biopharmaceutical earnings date?
Sino Biopharmaceutical is going to release the next earnings report on April 01, 2027.
What were Sino Biopharmaceutical earnings last quarter?
SBHMY earnings for the last quarter are 0.03 USD per share, whereas the estimation was 0.02 USD resulting in a +58.58% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Sino Biopharmaceutical revenue for the last year?
Sino Biopharmaceutical revenue for the last year amounts to 4.49B USD.
What is Sino Biopharmaceutical net income for the last year?
SBHMY net income for the last year is 323.63M USD.
Does Sino Biopharmaceutical pay dividends?
Yes, SBHMY dividends are paid semi-annual. The last dividend per share was 0.13 USD. As of today, Dividend Yield (FWD)% is 2.35%.
How many employees does Sino Biopharmaceutical have?
As of September 02, 2026, the company has 21,435 employees.
In which sector is Sino Biopharmaceutical located?
Sino Biopharmaceutical operates in the Health & Wellness sector.
When did Sino Biopharmaceutical complete a stock split?
The last stock split for Sino Biopharmaceutical was on August 14, 2020 with a ratio of 1.5:1.
Where is Sino Biopharmaceutical headquartered?
Sino Biopharmaceutical is headquartered in Hong Kong, Cayman Islands.